NASDAQ:NTGN - Neon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.66 -0.10 (-5.68 %) (As of 01/26/2020 04:45 AM ET) Add Compare Today's Range$1.62Now: $1.66▼$1.7850-Day Range$1.00MA: $1.26▼$1.8252-Week Range$0.88Now: $1.66▼$7.51Volume376,370 shsAverage Volume554,421 shsMarket Capitalization$47.04 millionP/E RatioN/ADividend YieldN/ABeta1.35 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTGN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.neontherapeutics.com/ Phone617-337-4701Debt Debt-to-Equity Ratio0.15 Current Ratio4.59 Quick Ratio4.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book0.46Profitability EPS (Most Recent Fiscal Year)($5.54) Net Income$-76,930,000.00 Net MarginsN/A Return on Equity-116.98% Return on Assets-95.27%Miscellaneous Employees102 Outstanding Shares28,340,000Market Cap$47.04 million Next Earnings Date3/9/2020 (Estimated) OptionableNot Optionable Receive NTGN News and Ratings via Email Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NTGN Rates by TradingView Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions What is Neon Therapeutics' stock symbol? Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN." How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) posted its earnings results on Tuesday, November, 12th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.04. View Neon Therapeutics' Earnings History. When is Neon Therapeutics' next earnings date? Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neon Therapeutics. What price target have analysts set for NTGN? 6 brokerages have issued 12-month target prices for Neon Therapeutics' stock. Their forecasts range from $2.18 to $15.00. On average, they expect Neon Therapeutics' share price to reach $10.24 in the next twelve months. This suggests a possible upside of 516.6% from the stock's current price. View Analyst Price Targets for Neon Therapeutics. What is the consensus analysts' recommendation for Neon Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neon Therapeutics. What are Wall Street analysts saying about Neon Therapeutics stock? Here are some recent quotes from research analysts about Neon Therapeutics stock: 1. According to Zacks Investment Research, "Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company's product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. " (1/4/2020) 2. HC Wainwright analysts commented, "Our assessment is driven by a discounted cash flow (DCF)-based approach, which utilizes a 10% discount rate, 1.0% terminal growth rate, and 30% probability of approval for NEO-PV-01 in front-line melanoma, NSCLC, and bladder cancer. We assume a 29% effective tax rate." (9/16/2019) Has Neon Therapeutics been receiving favorable news coverage? News headlines about NTGN stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neon Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Neon Therapeutics. Are investors shorting Neon Therapeutics? Neon Therapeutics saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 573,900 shares, a drop of 19.6% from the December 15th total of 713,900 shares. Based on an average daily trading volume, of 204,700 shares, the days-to-cover ratio is presently 2.8 days. Approximately 4.0% of the shares of the stock are short sold. View Neon Therapeutics' Current Options Chain. Who are some of Neon Therapeutics' key competitors? Some companies that are related to Neon Therapeutics include LogicBio Therapeutics (LOGC), Windtree Therapeutics (WINT), Solid Biosciences (SLDB), Applied Genetic Technologies (AGTC), Dyadic International (DYAI), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), X4 Pharmaceuticals (XFOR), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Gamida Cell (GMDA), Polarityte (PTE), Acorda Therapeutics (ACOR), Champions Oncology (CSBR) and Brainstorm Cell Therapeutics (BCLI). What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include AT&T (T), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP), Bank of America (BAC), Anavex Life Sciences (AVXL), Bellicum Pharmaceuticals (BLCM), Enphase Energy (ENPH), Galmed Pharmaceuticals (GLMD) and Opko Health (OPK). Who are Neon Therapeutics' key executives? Neon Therapeutics' management team includes the folowing people: Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)Dr. Eric S. Lander, Founder & Director (Age 62)Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)Dr. Richard Gaynor, Pres of R&D (Age 69)Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer When did Neon Therapeutics IPO? (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Neon Therapeutics' major shareholders? Neon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.88%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View Institutional Ownership Trends for Neon Therapeutics. Which major investors are buying Neon Therapeutics stock? NTGN stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Neon Therapeutics. How do I buy shares of Neon Therapeutics? Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Neon Therapeutics' stock price today? One share of NTGN stock can currently be purchased for approximately $1.66. How big of a company is Neon Therapeutics? Neon Therapeutics has a market capitalization of $47.04 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics. What is Neon Therapeutics' official website? The official website for Neon Therapeutics is http://www.neontherapeutics.com/. How can I contact Neon Therapeutics? Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected] MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 148 (Vote Underperform)Total Votes: 305MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: How does a dividend reinvestment plan work?
